2024
DOI: 10.1016/j.neuint.2023.105642
|View full text |Cite
|
Sign up to set email alerts
|

Matrix Metalloproteinase-9 inhibitors as therapeutic drugs for traumatic brain injury

Angel Sunny,
Raisa Rani James,
Swathi Radhakrishnan Menon
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 70 publications
0
2
0
Order By: Relevance
“…In conclusion, these results indicate that MMP-9 may possibly serve as a prognostic biomarker for development of Long-COVID and potential target for treatment. In fact, MMP-9 inhibitors have been considered for the treatment of traumatic brain injury (Sunny et al, 2024). In particular, the natural avonoid nobiletin has been reported to inhibit MMP-9 (Kim et al, 2014).…”
Section: Discussionmentioning
confidence: 99%
“…In conclusion, these results indicate that MMP-9 may possibly serve as a prognostic biomarker for development of Long-COVID and potential target for treatment. In fact, MMP-9 inhibitors have been considered for the treatment of traumatic brain injury (Sunny et al, 2024). In particular, the natural avonoid nobiletin has been reported to inhibit MMP-9 (Kim et al, 2014).…”
Section: Discussionmentioning
confidence: 99%
“…Notably, elevated MMP-9 in the epileptic human brain has also been documented [16,22]. Of note, recently, either partially or just poorly selective MMP-9 inhibitors have been shown to offer therapeutic potential towards epileptogenesis [23][24][25][26], further supporting the need to assess a role of MMP-9 in post-stroke epileptogenesis. Our results demonstrate that MMP-9 indeed plays a role in post-stroke epileptogenesis, by virtue of the enzyme activation by MCAO and findings that genetically modified MMP-9 levels (either gene knockout or gene overexpression) affect a seizure threshold following a chemoconvulsant (pentylenetetrazol, PTZ) treatment that is one of the widely recognized measures of susceptibility to develop epilepsy.…”
Section: Introductionmentioning
confidence: 96%